These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35759759)

  • 1. Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL.
    Yano M; Nunes J; Mo X; Rogers KA; Woyach JA; Byrd JC; Muthusamy N
    Blood Adv; 2022 Sep; 6(18):5440-5448. PubMed ID: 35759759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
    Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
    Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
    Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
    Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
    Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
    Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
    Reiff SD; Muhowski EM; Guinn D; Lehman A; Fabian CA; Cheney C; Mantel R; Smith L; Johnson AJ; Young WB; Johnson AR; Liu L; Byrd JC; Woyach JA
    Blood; 2018 Sep; 132(10):1039-1049. PubMed ID: 30018078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
    Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL
    Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
    Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
    Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
    Cheng S; Ma J; Guo A; Lu P; Leonard JP; Coleman M; Liu M; Buggy JJ; Furman RR; Wang YL
    Leukemia; 2014 Mar; 28(3):649-57. PubMed ID: 24270740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
    Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.
    Herman SE; Mustafa RZ; Jones J; Wong DH; Farooqui M; Wiestner A
    Clin Cancer Res; 2015 Oct; 21(20):4642-51. PubMed ID: 26089373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib treatment of CLL: the cancer fights back.
    Young RM; Staudt LM
    Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
    Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
    Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.
    Ren L; Campbell A; Fang H; Gautam S; Elavazhagan S; Fatehchand K; Mehta P; Stiff A; Reader BF; Mo X; Byrd JC; Carson WE; Butchar JP; Tridandapani S
    J Biol Chem; 2016 Feb; 291(6):3043-52. PubMed ID: 26627823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.